Arbutus Biopharma ABUS Income Statement (2010-2026)

NASDAQ ABUS
$5.14 +0.02 (+0.29%)
As of: Sep 4, 2026 · 11:45 AM EDT
Reported Financials

Arbutus Biopharma Quarterly Income Statement

Periods 57 quarters
Latest Jun 2026

Arbutus Biopharma reported revenue of $1.01M and net income of -$5.19M for the quarter ended Jun 2026, down 90.6% year over year. This income statement covers 57 quarters of results from Dec 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2010 Dec2011 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
3.34M3.21M12.58M14.24M5.95M6.25M6.69M4.65M4.66M2.15M1.53M1.73M1.34M1.57M1.76M10.74M0.53M1.05M179.13M1.01M
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot)
0.45M
Research & DevelopmentR&D
16.71M19.21M18.46M22.94M20.05M22.95M18.27M17.69M20.17M17.56M15.40M15.55M14.27M8.81M8.96M5.50M5.78M5.01M4.12M2.90M
Selling, General & AdministrativeSG&A
4.18M4.60M4.89M5.20M3.49M4.25M5.55M5.98M5.84M5.10M5.31M7.55M4.54M4.71M5.83M3.33M3.04M3.69M5.89M3.87M
Restructuring CostsRestructuring
3.62M0.10M12.37M0.17M0.10M0.30M
Other Operating ExpensesOther Opex
0.41M0.19M0.20M0.21M0.21M1.61M0.27M-0.64M0.20M0.23M0.18M0.21M0.34M1.89M0.30M0.26M0.27M-2.66M0.21M0.21M
Operating ExpensesOpex
21.75M24.00M23.55M28.35M23.76M28.81M24.10M23.04M26.22M22.89M20.89M23.31M22.78M15.51M27.46M9.25M9.19M6.34M10.22M6.98M
Operating IncomeOp. Inc
-18.41M-20.80M-10.97M-14.11M-17.81M-22.56M-17.41M-18.39M-21.56M-20.75M-19.36M-21.58M-21.44M-13.93M-25.70M1.49M-8.66M-5.29M168.91M-5.96M
EBIT
-18.41M-20.80M-10.97M-14.11M-17.81M-22.56M-17.41M-18.39M-21.56M-20.75M-19.36M-21.58M-21.44M-13.93M-25.70M1.49M-8.66M-5.29M168.91M-5.96M
Non-operating items
Non Operating Interest Expenses
0.76M0.56M0.51M0.48M0.43M0.31M0.20M0.17M0.05M0.04M0.04M0.03M0.03M0.03M0.03M0.03M0.02M0.02M0.02M0.02M
Non Operating Investment IncomeNon-Op. Investment Inc.
Interest & Investment IncomeInt & Inv Inc
0.03M0.03M0.16M0.40M0.69M0.94M1.27M1.46M1.49M1.47M1.54M1.83M1.75M1.46M1.20M1.04M0.95M0.88M0.81M0.84M
Other Non Operating IncomeOther Non Op Inc.
-0.01M0.01M0.00M-0.02M-0.00M0.00M0.00M0.01M0.01M-0.01M-0.01M0.01M-0.03M0.00M0.02M-0.01M0.00M-0.01M-0.00M
Non Operating IncomeNon Op. Inc.
-0.75M-0.53M-0.35M-0.08M0.24M0.63M1.07M1.29M1.45M1.44M1.49M1.79M1.72M1.40M1.17M1.03M0.92M1.53M0.79M0.82M
Net income details
EBT
-19.16M-21.32M-11.32M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Tax ProvisionsTaxes
4.44M
Profit After TaxPAT
-19.19M-21.47M-15.77M-14.19M-18.47M-21.42M-16.34M-17.09M-20.10M-19.31M-17.88M-19.80M-19.72M-12.53M-24.53M2.52M-7.74M-3.76M169.69M-5.19M
Equity Income
Income from Continuing OperationsIncome (Continuing)
-19.16M-21.32M-15.77M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Consolidated Net IncomeConsol Net Inc.
-19.16M-21.32M-15.77M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Income towards Parent CompanyParent Net Inc
-19.16M-21.32M-15.77M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Preferred Dividend PaymentsPref Dividends
5.09M0.57M
Net Income towards Common StockholdersNet Income
-24.25M-21.89M-15.77M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Additional items
EPS (Basic)
-0.24-0.21-0.11-0.10-0.12-0.15-0.10-0.10-0.12-0.12-0.10-0.11-0.10-0.07-0.130.01-0.04-0.020.88-0.03
EPS (Diluted)
-0.24-0.21-0.11-0.10-0.12-0.15-0.10-0.10-0.12-0.12-0.10-0.11-0.10-0.07-0.130.01-0.04-0.020.87-0.03
Shares Outstanding
101.29M106.24M148.43M148.75M151.00M150.94M161.64M166.06M167.51M165.96M175.63M188.04M189.00M185.61M190.71M191.55M191.78M191.60M193.77M197.47M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
101.29M106.24M148.43M148.75M151.00M150.94M161.64M166.06M167.51M165.96M175.63M188.04M189.00M185.61M190.71M192.40M191.78M191.60M195.21M197.47M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
110.26M106.24M148.73M148.79M152.71M157.46M165.13M166.92M167.70M169.87M180.19M188.74M189.44M189.96M191.48M191.64M191.95M192.53M196.95M197.63M
EBITDA
-17.96M-20.80M-10.97M-14.11M-17.81M-22.56M-17.41M-18.39M-21.56M-20.75M-19.36M-21.58M-21.44M-13.93M-25.70M1.49M-8.66M-5.29M168.91M-5.96M
Interest ExpensesInt Expense
0.76M0.56M0.51M0.48M0.43M0.31M0.20M0.17M0.05M0.04M0.04M0.03M0.03M0.03M0.03M0.03M0.02M0.02M0.02M0.02M
Tax Rate
-39.25%